ArticleFrontiers in oncology2026
The role of postmastectomy radiotherapy in male breast cancer: a multicenter retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Male breast cancer (MBC) is a rare malignancy, accounting for about 1% of all breast cancers. Treatment guidelines are largely extrapolated from female breast cancer (FBC) studies, with limited MBC-specific evidence. This study evaluates the impact of postmastectomy radiotherapy (PMRT) on survival outcomes in MBC. Methods: We conducted a retrospective cohort study using the SEER database (2004-2015) and the Shanghai Jiao Tong University Breast Cancer Data Base (SJTUBCDB). Included were MBC patients with T1-2N1M0 disease after mastectomy. Inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics. Overall survival (OS), breast cancer-specific survival (BCSS), and disease-free survival (DFS) were compared between PMRT and non-PMRT groups. Competing risks were accounted for in BCSS analysis using the Fine-Gray subdistribution hazard model. Subgroup analyses were based on tumor size, lymph node involvement, and hormone receptor status. Results: Of 714 eligible SEER patients, 33.9% received PMRT. PMRT was associated with improved OS (HR 0.79, 95% CI 0.53-0.94), especially in patients with T2 tumors, 2-3 positive lymph nodes, or negative progesterone receptor (PR) status. Competing risk analysis confirmed no significant difference in BCSS (subdistribution HR 0.79, 95% CI 0.44-1.42). No significant difference in BCSS was observed. In the SJTUBCDB cohort (n=50), similar directional trends were noted: PMRT was linked to better OS and DFS in high-risk subgroups, particularly in Luminal B subtypes and patients with T2 tumors or multiple involved lymph nodes. Conclusion: PMRT was associated with improved OS in selected MBC patients with high-risk features such as larger tumors or PR-negative disease. The consistent findings from SEER and SJTUBCDB support the use of PMRT in high-risk MBC patients and highlight the need for personalized treatment strategies and prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.